BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 37208379)

  • 1. Prosaposin PS18 reduces dopaminergic neurodegeneration in a 6-hydroxydopamine rat model of Parkinson's disease.
    Wu KJ; Hung TW; Wang YS; Chen YH; Bae EK; Yu SJ
    Sci Rep; 2023 May; 13(1):8148. PubMed ID: 37208379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Attenuation of MPTP/MPP(+) toxicity in vivo and in vitro by an 18-mer peptide derived from prosaposin.
    Gao HL; Li C; Nabeka H; Shimokawa T; Saito S; Wang ZY; Cao YM; Matsuda S
    Neuroscience; 2013 Apr; 236():373-93. PubMed ID: 23321539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson's disease.
    Oiwa Y; Yoshimura R; Nakai K; Itakura T
    Brain Res; 2002 Aug; 947(2):271-83. PubMed ID: 12176170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic effects of multifunctional tetramethylpyrazine nitrone on models of Parkinson's disease in vitro and in vivo.
    Guo B; Xu D; Duan H; Du J; Zhang Z; Lee SM; Wang Y
    Biol Pharm Bull; 2014; 37(2):274-85. PubMed ID: 24305623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early post-treatment with 9-cis retinoic acid reduces neurodegeneration of dopaminergic neurons in a rat model of Parkinson's disease.
    Yin LH; Shen H; Diaz-Ruiz O; Bäckman CM; Bae E; Yu SJ; Wang Y
    BMC Neurosci; 2012 Oct; 13():120. PubMed ID: 23040108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurotrophic and neuroprotective efficacy of intranasal GDNF in a rat model of Parkinson's disease.
    Migliore MM; Ortiz R; Dye S; Campbell RB; Amiji MM; Waszczak BL
    Neuroscience; 2014 Aug; 274():11-23. PubMed ID: 24845869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rosiglitazone, a PPAR-γ agonist, protects against striatal dopaminergic neurodegeneration induced by 6-OHDA lesions in the substantia nigra of rats.
    Lee EY; Lee JE; Park JH; Shin IC; Koh HC
    Toxicol Lett; 2012 Sep; 213(3):332-44. PubMed ID: 22842585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of (-)-sesamin on 6-hydroxydopamine-induced neurotoxicity in PC12 cells and dopaminergic neuronal cells of Parkinson's disease rat models.
    Park HJ; Zhao TT; Lee KS; Lee SH; Shin KS; Park KH; Choi HS; Lee MK
    Neurochem Int; 2015; 83-84():19-27. PubMed ID: 25747493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytisine is neuroprotective in female but not male 6-hydroxydopamine lesioned parkinsonian mice and acts in combination with 17-β-estradiol to inhibit apoptotic endoplasmic reticulum stress in dopaminergic neurons.
    Zarate SM; Pandey G; Chilukuri S; Garcia JA; Cude B; Storey S; Salem NA; Bancroft EA; Hook M; Srinivasan R
    J Neurochem; 2021 May; 157(3):710-726. PubMed ID: 33354763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative study of the neurotrophic effects elicited by VEGF-B and GDNF in preclinical in vivo models of Parkinson's disease.
    Yue X; Hariri DJ; Caballero B; Zhang S; Bartlett MJ; Kaut O; Mount DW; Wüllner U; Sherman SJ; Falk T
    Neuroscience; 2014 Jan; 258():385-400. PubMed ID: 24291725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroprotection with the cannabigerol quinone derivative VCE-003.2 and its analogs CBGA-Q and CBGA-Q-Salt in Parkinson's disease using 6-hydroxydopamine-lesioned mice.
    Burgaz S; García C; Gómez-Cañas M; Navarrete C; García-Martín A; Rolland A; Del Río C; Casarejos MJ; Muñoz E; Gonzalo-Consuegra C; Muñoz E; Fernández-Ruiz J
    Mol Cell Neurosci; 2021 Jan; 110():103583. PubMed ID: 33338634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alterations of the nigrostriatal pathway in a 6-OHDA rat model of Parkinson's disease evaluated with multimodal MRI.
    Perlbarg V; Lambert J; Butler B; Felfli M; Valabrègue R; Privat AL; Lehéricy S; Petiet A
    PLoS One; 2018; 13(9):e0202597. PubMed ID: 30188909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. STAT3 protects dopaminergic neurons against degeneration in animal model of Parkinson's disease.
    Smit RD; Ghosh B; Campion TJ; Stingel R; Lavell E; Hooper R; Fan X; Soboloff J; Smith GM
    Brain Res; 2024 Feb; 1824():148691. PubMed ID: 38030102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Aging on the 6-OHDA-Induced Rat Model of Parkinson's Disease.
    Barata-Antunes S; Teixeira FG; Mendes-Pinheiro B; Domingues AV; Vilaça-Faria H; Marote A; Silva D; Sousa RA; Salgado AJ
    Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32422916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intranigral ventral mesencephalic grafts and nigrostriatal injections of glial cell line-derived neurotrophic factor restore dopamine release in the striatum of 6-hydroxydopamine-lesioned rats.
    Tang FI; Tien LT; Zhou FC; Hoffer BJ; Wang Y
    Exp Brain Res; 1998 Apr; 119(3):287-96. PubMed ID: 9551829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RING finger protein 11 (RNF11) modulates susceptibility to 6-OHDA-induced nigral degeneration and behavioral deficits through NF-κB signaling in dopaminergic cells.
    Pranski EL; Dalal NV; Sanford CV; Herskowitz JH; Gearing M; Lazo C; Miller GW; Lah JJ; Levey AI; Betarbet RS
    Neurobiol Dis; 2013 Jun; 54():264-79. PubMed ID: 23318928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vitamin D(3) attenuates 6-hydroxydopamine-induced neurotoxicity in rats.
    Wang JY; Wu JN; Cherng TL; Hoffer BJ; Chen HH; Borlongan CV; Wang Y
    Brain Res; 2001 Jun; 904(1):67-75. PubMed ID: 11516412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myricitrin Ameliorates 6-Hydroxydopamine-Induced Dopaminergic Neuronal Loss in the Substantia Nigra of Mouse Brain.
    Kim HD; Jeong KH; Jung UJ; Kim SR
    J Med Food; 2016 Apr; 19(4):374-82. PubMed ID: 26991235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in rat partial and full nigral 6-hydroxydopamine lesion models of Parkinson's disease.
    Hansen HH; Fabricius K; Barkholt P; Mikkelsen JD; Jelsing J; Pyke C; Knudsen LB; Vrang N
    Brain Res; 2016 Sep; 1646():354-365. PubMed ID: 27233809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroprotective effect of hydroxysafflor yellow A on 6-hydroxydopamine-induced Parkinson's disease in rats.
    Han B; Hu J; Shen J; Gao Y; Lu Y; Wang T
    Eur J Pharmacol; 2013 Aug; 714(1-3):83-8. PubMed ID: 23791614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.